Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Public Knowledge-Based Application Filed for Colchicine for Familial Mediterranean Fever
March 25, 2016
- MSD Going Full Out for Sakigake-Designated Pembrolizumab, Poised to Bolster Oncology Force
March 25, 2016
- Lilly Japan Logs 236 Billion Yen in 2015, Set to Further Boost Sales Force from 2,000
March 25, 2016
- Sosei Group Taps GSK Veteran Peter Bains as Next CEO
March 24, 2016
- Eisai Withdraws Japan NDA for Ultra-High Dose Mecobalamin for ALS
March 24, 2016
- Hengrui to Apply for Sakigake Designation; Develop New Drugs Alongside Generics in Japan
March 24, 2016
- Eisai to Return US Rights to Helsinn’s Antiemetic Akynzeo
March 23, 2016
- Valixa Filed for Prevention of CMV Disease in Organ Transplants: Mitsubishi Tanabe
March 23, 2016
- Romosozumab Yields Positive PIII Data in Male Osteoporosis: Amgen Astellas
March 23, 2016
- Higher Remission Rates in TNF Blocker-Naïve Patients Observed in Long-Term Vedolizumab Treatment
March 23, 2016
- Santen to Form JV with China’s Kerui for Generic Eye Drugs
March 23, 2016
- Opdivo Filed for Hodgkin’s Lymphoma in Japan
March 22, 2016
- Mochida to Codevelop Ajinomoto’s Oral Constipation Drug
March 22, 2016
- Jitsubo Aims to Launch Peptide Generic Drugs Using Its Unique Technologies
March 22, 2016
- Drug Makers Terminate Lysozyme, Pronase Sale after MHLW Panel Finds Them Ineffective
March 18, 2016
- Hisamitsu, Asahi Kasei End Sales Partnership for Neoxy Tape
March 18, 2016
- Meiji Seika Pharma, RIKEN Collaborate on Skin Regeneration Research
March 17, 2016
- Takeda, Orexigen to Wind Up Sales Collaboration for Contrave
March 17, 2016
- Reversal Agent for Prazaxa Filed in Japan: Boehringer
March 17, 2016
- Denka Seiken to Develop Intradermal Flu Vaccine
March 16, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…